Association of 21-Gene Assay (OncotypeDX) Testing and Receipt of Chemotherapy in the Medicare Breast Cancer Patient Population Following Initial Adoption-Reference-Cited by-同舟云学术

Association of 21-Gene Assay (OncotypeDX) Testing and Receipt of Chemotherapy in the Medicare Breast Cancer Patient Population Following Initial Adoption

Published:2020-12 Issue:6 Volume:20 Page:487-494.e1
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Dinan Michaela A.^ORCID,Wilson Lauren E.^ORCID,Reed Shelby D.,Griggs Jennifer J.^ORCID,Norton Edward C.^ORCID

Funder

AstraZeneca

Abbott Vascular Business

Amgen

Amylin Pharmaceuticals

Duke Clinical Research Institute

Evalve, Inc

Food and Drug Administration

Genzyme

Grifols

Janssen Research and Development

Lundbeck Pharmaceuticals

Medical Device Innovation Consortium

Merck & Co

Minomic International

Monteris

SVC Systems

TESARO Inc

Zimmer Biomet

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference25 articles.

1. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer;Paik;N Engl J Med,2004

2. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer;Paik;J Clin Oncol,2006

3. The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort;Ademuyiwa;Breast Cancer Res Treat,2011

4. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?;Asad;Am J Surg,2008

5. A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score(R) assay in oestrogen receptor positive node negative breast cancer;Davidson;Eur J Cancer,2013

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analyzing Precision Medicine Utilization with Real-World Data: A Scoping Review;Journal of Personalized Medicine;2022-04-01